Effect of Digitalis (cas 1339-93-1) level on readmission and mortality rate among heart failure reduced ejection fraction patients

Add time:08/31/2019    Source:sciencedirect.com

IntroductionDigitalis (cas 1339-93-1) has been used for over 200 years to treat patients with heart failure, and evidence supports its use to improve clinical symptoms and quality of life, but not survival. The objective of this retrospective study was to evaluate the effects of digitalis on readmission and mortality in patients with heart failure with reduced ejection fraction (HFrEF) who were receiving current guideline recommended medical therapy.

We also recommend Trading Suppliers and Manufacturers of Digitalis (cas 1339-93-1). Pls Click Website Link as below: cas 1339-93-1 suppliers

Prev:Case ReportDigoxin-specific Fab and therapeutic plasma exchange for Digitalis (cas 1339-93-1) intoxication and renal failure
Next:Alternans during fascicular ventricular tachycardia due to Digitalis (cas 1339-93-1) toxicity)